The Impact of Interscalene Block on Sleep Disordered Breathing

Obstructive Sleep Apnea Clinical Trial

— OSA-ISB  

Official title:

Evaluating the Impact of Interscalene Brachial Plexus Block on Sleep-disordered Breathing in Patients Undergoing Ambulatory Shoulder Surgery. A Two-arm, Prospective, Parallel, Double Blind Randomized -Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03718858
• Other study ID #: 2018-0037-B
• Status: Recruiting
• Phase: N/A
• Start date: July 23, 2021
• Est. completion date: September 2024

Study information

• Verified date: April 2023
• Source: Women's College Hospital
• Contact: Laurentia Enesi
• Phone: (416)323 6400
• Email: Laurentia.Enesi[@]wchospital.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized controlled trial evaluating the impact of interscalene block on worsening of upper airway collapse in sleep disordered breathing for patients undergoing ambulatory shoulder surgery.

Description:

Sleep disordered Breathing (SDB), closely associated with obesity, is a highly prevalent, serious, and often unrecognized breathing disorder resulting from repeated upper airway collapse, decreased oxygen levels, and a very high risk of life threatening complications at the time of surgery. Current guidelines recommend using regional as opposed to general anesthesia in SDB patients to minimize risks and the use of strong narcotic medications. It is unclear whether interscalene block in use for analgesia (pain relief) may actually worsen the severity of SDB by invariably freezing the phrenic nerve, thereby temporarily paralyzing the diaphragm. This novel clinical trial will examine whether or not ISB increases the rate of upper airway obstruction or collapse during sleep and other dangerous postoperative complications seen in patients with SDB following shoulder surgeries. The Primary Objective of the study is to evaluate the impact of ISB on the oxygen desaturation index (sleep apnea severity) in untreated SDB patients undergoing ambulatory shoulder surgery compared to patients who do not receive ISB. Secondary Objectives are: 1) To evaluate the impact of hemidiaphragmatic paresis on impairment in pulmonary function; 2) To evaluate the impact of impairment in pulmonary function on the oxygen desaturation index (ODI); 3) To assess the incidence of important perioperative clinical outcomes such as hypoxemia, recurrent respiratory events, delayed discharge, and resource utilization in SDB patients undergoing ambulatory shoulder surgery compared to patients who do not receive ISB; and 4) To assess important analgesia related outcomes such as: time to onset of pain, intraoperative and postoperative opioid consumption, hourly and daily VAS pain scores, opioid related side effects, patient satisfaction with analgesia, and presence/absence of nerve block complications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: September 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Adult patients ( >18 to 80 years);
• American Society of Anesthesiology (ASA) physical status I-IV;
• Undergoing elective ambulatory shoulder surgery such as shoulder replacement, acromioplasty, rotator cuff repair, or Bankart procedure under general anesthesia.

Exclusion Criteria:

• Past history of head, neck or thoracic surgery (e.g., OSA corrective surgery);
• Pregnancy or lactation;
• Phrenic nerve stimulators;
• Local anesthetic allergy;
• Previous diaphragmatic paralysis;
• Inability to communicate with health care providers or the research personnel, inability to perform breathing maneuvers such as spirometry, or inability to follow instructions.

Related Conditions & MeSH terms

• Obstructive Sleep Apnea
• Respiratory Aspiration
• Sleep Apnea Syndromes
• Sleep Apnea, Obstructive
• Sleep Disordered Breathing

Intervention

Procedure:
• Interscalene Block
15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
• Superior Trunk Nerve Block
15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to Superior Trunk Nerve.

Locations

Country	Name	City	State
Canada	Toronto Western Hospital	Toronto	Ontario
Canada	Women's College Hospital	Toronto	ON Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Women's College Hospital	University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Oxygen desaturation index (ODI) from baseline to the night of surgery (post- operation) (N1).	All patients will undergo a portable overnight oximetry study at home to establish the baseline oxygen saturation measured hourly. Oxygen Desaturation Index (ODI), which is defined as a 4% drop in oxygenation from the baseline, and calculated as events occurring per hour during the recording time; the minimum and mean oxygen saturation ; and the cumulative total of recoded time below an oxygen saturation of 90%, CT90). Patients with preoperative ODI with more than a score of 10 will be considered at risk of SDB. A change from baseline will be examined and compared between the two groups.	Time of measurements will be at baseline (pre operatively) and within 24 hours post-operatively (night of surgery)
Secondary	Change in amplitude of diaphragmatic excursion with breathing maneuvers, between before and after surgery (measured by ultrasound)	Rate of diaphragmatic function (complete, partial, or none) will be assessed before and after surgery using M-Mode Ultrasound. Assessment will be performed during quiet breathing, sniffing, and deep breathing. After surgery diaphragmatic paresis will be indicated by a flat trace (absence of excursion) with quiet and deep breathing and/or with paradoxical motion. Measurement of amplitude of excursion will be made when partial paresis is observed. Using the sniff maneuver, complete hemi-diaphragmatic paresis (reduction of >75% from baseline) and partial paresis (reduction of 25-75%from baseline) will be recorded. Rate will be assessed in the basal state (i.e. before regional anesthesia) to establish a baseline, and again in the post-operative period.	Time of measurements will be within 1 hour before surgery, and within 1 hour after surgery. It will take around 10-15 minutes.
Secondary	Change in pulmonary function before and after surgery, as measured by bedside spirometry	Change in pulmonary function tests [Forced vital capacity (FVC), forced expiratory volume in 1s (FEV1), Expiratory reserve volume (ERV) and peak expiratory flow (PEF) ], between before and after surgery will be measured by bedside spirometry	Time of measurements will be within 1 hour before surgery, and within 1 hour after surgery. It will take around 5-10 minutes.
Secondary	Post operative respiratory events	Respiratory events in recovery room (Oxygen saturation < 90% (3 episodes), bradypnea < 8 breaths / min (3 episodes), apnea = 10s (1 episode) will be recorded.	Within 24 hours of the time of surgery
Secondary	Visual Analogue Scale (VAS) pain scores	Measurement of hourly and daily Visual Analogue Scale (VAS) pain scores. VAS: 10cm scale where 0=no pain, 10=worst pain.	8 hours and 24 hours after surgery.
Secondary	Analgesia requirements	Opioid and other pain killers consumption will be recorded intra and post-operatively	Day 1 of surgery.
Secondary	Patient satisfaction with analgesia	A follow up call will be made on day 1 and day 30 to collect overall satisfaction with pain control. Overall satisfaction will be assessed on a 7-point Likert scale of 1-not at all satisfied with pain control, 2-mostly unsatisfied with pain control, 3-slightly unsatisfied with pain control, 4-no opinion, 5-slightly satisfied with pain control, 6-mostly satisfied with pain control, 7-completely satisfied with pain control	8 hours and 24 hours after surgery.